TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00045968
Drug: Dendritic cell immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
Study: NCT03907280
Drug: BI 1265162 (T1)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT03907280
Drug: BI 1265162 (T2)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for inhalation
Study: NCT03907280
Drug: BI 1265162 (T3)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for inhalation
Study: NCT03904862
Drug: CX 4945
Normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API
Study: NCT00736320
Drug: ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chemotherapy with 2 cycles of ABVD (day 1 + 15)
Study: NCT00246974
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous
Study: NCT00246974
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous
Study: NCT00246974
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01854658
Drug: GFF MDI (PT003)
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI administered as two puffs BID
Study: NCT01854658
Drug: FF MDI (PT005)
Normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF MDI administered as two puffs BID
Study: NCT00685542
Drug: diacerein
Normalized name: diacerein
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein 50mg bid
Study: NCT03025841
Drug: Ceftaroline
Normalized name: Ceftaroline
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01693484
Drug: ICG (Indocyanine Green)
Normalized name: Indocyanine Green
DrugBank: Water (DB09145)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
Study: NCT03316859
Drug: Naloxegol 25 MG
Normalized name: naloxegol 25 MG
DrugBank: Naloxegol (DB09049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Naloxegol 25 mg administered 1 hour pre-operatively
Study: NCT04618913
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anticoagulant
Study: NCT04618913
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anticoagulant
Study: NCT04618913
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Edoxaban
Study: NCT04618913
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran
Study: NCT04618913
Drug: VKA
Normalized name: METHYLPHENIDATE HCL (AVKARE) 18MG SA TAB
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin K antagonist
Study: NCT01928394
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03814759
Drug: TS-1 + cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-1 20mg/m2, bid (D1\~14, D22\~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)
Study: NCT01216111
Drug: Paclitaxel Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel 80 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15~1 cycle = 28days~PC\*6
Study: NCT03825757
Drug: Acetyl Salicylic Acid
Normalized name: Acetyl salicylic acid specific IgE
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaspan 250 mg tablet Acetyl Salicylic Acid
Study: NCT00418639
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00819728
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35mg/m2 IV each week for 4 weeks
Study: NCT00819728
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg/m2 IV each week for 4 weeks
Study: NCT00048360
Drug: Extended-release bupropion hydrochloride
Normalized name: bupropion Extended Release Oral Tablet
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01066494
Drug: Amonafide + cytarabine
Normalized name: amonafide
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
Study: NCT02038777
Drug: PF-04449913
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04449913 administered orally and continuously in 28 day cycles.
Study: NCT02038777
Drug: Low dose ARA-C (LDAC)
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
Study: NCT02038777
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin given using 60 mg/m2 for 3-days.
Study: NCT02038777
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 100 mg/m2 on days 1 through 7.
Study: NCT02038777
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
Study: NCT02038777
Drug: LDAC
Normalized name: Aldactone
DrugBank: Tildacerfont (DB18545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
Study: NCT03670056
Drug: Combination immunotherapy with Ipilimumab and Nivolumab
Normalized name: nivolumab and relatlimab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
Study: NCT02174939
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet (100 mg) twice per day for 12 weeks
Study: NCT01182610
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 9mg/kg on Days 1, 22, and 43
Study: NCT01182610
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200mg/m2 on Days 1 and 22
Study: NCT01182610
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC=6 on Days 1 and 22
Study: NCT03267836
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -10mg/kg IV
Study: NCT03493425
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03493425
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03493425
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04659733
Drug: Anlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib are divided into 3 dosage levels, including 8mg, 10mg, 12mg; Oral administration of anlotinib was given, qd, D1-D14; taken on an empty stomach, Every 3 weeks is a cycle, a total of 2 cycles; Starting from the first level of anlotinib, the dose will be ramped up in sequence.
Study: NCT03386318
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Serum concentration per hour from 1 to 5 h
Study: NCT02019004
Drug: Onabotulinum Toxin A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT02019004
Drug: Incobotulinum Toxin A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT03138603
Drug: Metoprolol Tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomly assigned to receive up-to-three intravenous doses of 5mg metoprolol tartrate (over 15-minutes) at the end of their surgical procedure, and a scheduled oral dose regimen of 25mg metoprolol approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
Study: NCT03231085
Drug: Ferrous fumarate or ferrostrane
Normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.
Study: NCT02506647
Drug: Gan & Lee insulin glargine followed by Lantus
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.4 IU/kg Gan \& Lee insulin glargine injection SC, Lantus 0.4 IU/kg injection SC
Study: NCT02506647
Drug: Lantus followed by Gan & Lee insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lantus 0.4 IU/kg injection SC, 0.4 IU/kg Gan \& Lee insulin glargine injection SC,
Study: NCT02202837
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: etanercept 1 x 50 mg/week or 2 x 25mg/week
Study: NCT01190683
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60,000 IU/week for ist eight weeks followed by 60,000 IU every 15 days for four months
Study: NCT01190683
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months
Study: NCT02457858
Drug: Islet isolation using BMX-010
Normalized name: BMX-001 free base
DrugBank: BMX-001 free base (DB17516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMX-010 will be used as a supplement in islet isolation process.
Study: NCT02638831
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
Study: NCT02219191
Drug: puerarin tablet 50 mg
Normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02219191
Drug: Atorvastatin tablet 20 mg
Normalized name: atorvastatin Oral Tablet
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approval No.: H19990258
Study: NCT04170179
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study: NCT04170179
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg intravenously every 3 weeks
Study: NCT04418674
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in this group, patient will receive ketamine at 0.3mg/kg intravenously.
Study: NCT00112008
Drug: De Novo Administration of Darbepoetin Alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL
Study: NCT01565720
Drug: Isavuconazole
Normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01565720
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT04540276
Drug: Inspiratory oxygen fraction
Normalized name: LIVER FRACTION
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Median inspiratory oxygen fraction during general anesthesia
Study: NCT03950570
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In patients with relapsed. metastatic breast cancer, ORIN1001 will be administered in combination with Abraxane administered by intravenous infusion.
Study: NCT01352650
Drug: plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.
Study: NCT01352650
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles
Study: NCT00291395
Drug: PGI2
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01464827
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
Study: NCT03463044
Drug: nangibotide
Normalized name: Nangibotide
DrugBank: Nangibotide (DB16247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continous i.v. infusion
Study: NCT01464827
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir capsules
Study: NCT01414465
Drug: Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
Study: NCT00544765
Drug: NX
Normalized name: BNX
DrugBank: Oxybuprocaine (DB00892)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m² as a \< 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
Study: NCT02841306
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02507206
Drug: DAR 0-100A
Normalized name: DAR-0100A
DrugBank: DAR-0100A (DB16139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
Study: NCT00810732
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)
Study: NCT03460275
Drug: Osimertinib Mesylate Tablets
Normalized name: Osimertinib Mesylate
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib 80mg oral administration daily until progression or occurring intolerable treatment-related toxic effects or patients withdrawing informed consent(Based on whichever occurs first)
Study: NCT03618550
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
Study: NCT03618550
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Study: NCT03618550
Drug: vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Study: NCT04641143
Drug: Troriluzole
Normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troriluzole - 2 100mg capsules QD for the first two weeks.
Study: NCT02710071
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebivolol 5mg then nebivolol 10 mg
Study: NCT02710071
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
Study: NCT00546104
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
Study: NCT03650582
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal glucagon
Study: NCT04152629
Drug: Methylphenidate Hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)
Study: NCT04152629
Drug: Lisdexamfetamine Dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)
Study: NCT03940430
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
Study: NCT03940430
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
Study: NCT04604184
Drug: BI 764198
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764198
Study: NCT01799590
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
Study: NCT00085709
Drug: gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV, induction Arm1 6mg/m2 D4; post-consolidation 5mg/m2 3 doses \>/= 28 days apart
Study: NCT00085709
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV; induction Arms1/2 and reinduction 100 mg/m2/d days 1-7; consolidation 3gm/m2 q3hrs D1, 3, 5
Study: NCT01711021
Drug: d-Amphetamine Transdermal Patch
Normalized name: amphetamine / dextroamphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
Study: NCT00085709
Drug: Daunomycin
Normalized name: Daunomycin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV; induction Arm1 45mg/m2 D1-3; Arm2 and reinduction 60 mg/m2 D1-3;
Study: NCT04725422
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Study: NCT04725422
Drug: Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Study: NCT04725422
Drug: Pamidronate
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Study: NCT04725422
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Study: NCT01499875
Drug: Phenoxymethylpenicillin
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mixture, 25 or 50 mg/kg taken once.
Study: NCT04725422
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Study: NCT02711956
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes